Biogen's MS drug misses main goal in mid-stage study
June 07, 2016 at 07:59 AM EDT
June 7 (Reuters) - Biogen Inc said its experimental drug for treating multiple sclerosis, a nervous system disease affecting the brain and the spinal cord, did not meet the main goal of improving some symptoms in a mid-stage study.
